BillionToOne shares slid from a prior close of $113.89 to $104.19, a -8.52% drop, during regular trading hours. The decline followed a strong Q3 report released Nov. 4 after the close — EPS of $0.32 doubled the $0.16 consensus and revenue rose +47% to $123M with raised guidance — but the stock sold off on profit-taking and concerns about Medicare reimbursement timing and true-up revenue sustainability.
Veracyte (VCYT) shares crashed from a prior close of $52.52 to $24.28, a -53.77% move, during regular market hours after already sliding in after-hours and premarket trading. The drop followed Q3 2026 results released after the Nov. 4 close: revenue ($151.8M) and adjusted EPS ($0.51) beat consensus, but management reset guidance — cutting FY26 revenue to $590–593M and guiding to only mid-single-digit 2027 revenue growth as Decipher Prostate volume missed targets for a second straight quarter.
Third quarter 2026 revenue came in at $202.7 million , down 1% year over year but ahead of the S&P consensus estimate of roughly $191 million. Adjusted loss per share of $0.11 beat the consensus estimate of about -$0.20, while GAAP (Generally Accepted Accounting Principles) net loss widened to $43.9 million, or $0.46 per share.
OPKO Health reported a third-quarter 2026 GAAP (Generally Accepted Accounting Principles) loss of $0.05 per share, narrower than the consensus estimate of a $0.07 loss. Continuing operations revenue grew 16% year over year to $65.4 million, driven by higher Lilly royalties, Rayaldee sales, and international growth.
Veracyte reported third quarter 2026 total revenue of $151.8 million , up 15.1% year over year and above the consensus estimate of roughly $147.2 million. Non-GAAP earnings per share (EPS, or profit divided by shares outstanding) came in at $0.51 , beating the consensus estimate of $0.41 by $0.10.
Adaptive Biotechnologies reported third quarter 2026 revenue of $83.9 million , up 39% year over year and well above the roughly $71.6 million consensus estimate. Earnings per share (EPS) came in at $0.02 , a sharp swing above the consensus expectation of a $0.10 loss, marking a rare GAAP-profitable quarter for the company.
BillionToOne reported third-quarter 2026 revenue of $122.98 million , up 47% year over year and above consensus estimates of roughly $115.8 million. Diluted earnings per share (EPS) came in at $0.32 , topping the consensus estimate of about $0.30, with net income of $17.4 million.
GRAIL reported third quarter 2026 revenue of $37.5 million , up 4% year over year but well below the analyst consensus of roughly $45 million. Net loss widened to $103.6 million , compared with $89.0 million a year earlier, while the loss per share came in at $2.21.
Net sales rose 3% year over year to $548 million in the third quarter of 2026, matching the company's preliminary figures released in late October. Adjusted diluted earnings per share (EPS) of $0.65 came in ahead of the company's own outlook of at least $0.62 at constant exchange rates (CER).
Charles River Laboratories is expected to report its third-quarter 2026 results in early November, following a second quarter that delivered the company's first organic revenue growth since 2023. Management has guided for organic revenue to turn positive again in the third quarter, led by accelerating demand in its Discovery and Safety Assessment (DSA) segment.
The central target of $7.50 is not an analyst consensus; it is a fallback objective grounded in the company's book value per share of roughly $7.43 and technical-reference levels. The latest verified price is about $2.20 (Nov. 3, 2026 close), leaving a required upside of roughly 240% to reach $7.50.
Advanced Biomed (ADVB) fell roughly 65% over the trailing 30 days, from a close of $6.34 on October 5 to $2.20 at the November 3 close. The decline extends a broader slide from the stock's 52-week intraday high of $24.23 reached in July 2026.
Recovery is broadening: Organic growth accelerated to 6% in the third quarter of 2026, driven by a rebound in pharma and biotech spending — the segment that accounts for roughly 60% of revenue — as well as industrial and applied markets. AI is becoming a structural catalyst: Management is embedding artificial intelligence across instruments, cryo-electron microscopy, and clinical research, positioning the company to benefit from faster, more efficient drug development.
The central target of $775 is the average of verified analyst price targets that sit above the current share price, not a headline consensus figure. The overall mean of all valid analyst targets reviewed was about $752, within a wide low-to-high range of roughly $590 to $830.
Thermo Fisher Scientific (TMO) shares recently traded near $698, up roughly 6% over the trailing month but still well within a broader consolidation range. Third-quarter revenue rose 9% to $12.14 billion, with 6% organic growth, while adjusted EPS climbed 15% to $6.68, beating consensus estimates.
Personalis is expected to report third-quarter 2026 results after market close, with consensus calling for a net loss of about $0.26 per share. Wall Street projects revenue near $21.5 million, up sharply from $14.5 million in the same quarter a year earlier.
Third-quarter 2026 revenue rose 4.4% year over year to $324.9 million, topping consensus estimates of roughly $319.7 million. Adjusted earnings per share (EPS) of $0.29 beat the $0.27 consensus and climbed 12% versus the prior-year period.
Revvity reported third-quarter 2026 revenue of $728.9 million , up 4.3% year over year, with pro forma organic growth of 7%. Adjusted earnings per share (EPS) rose roughly 17% to $1.38 , beating consensus estimates near $1.30.
Waters reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share (EPS) of $4.10 , topping consensus estimates of $1.75 billion and $4.00. Adjusted EPS climbed 21% year over year, while GAAP (Generally Accepted Accounting Principles) net income declined due to acquisition-related and restructuring costs.
The $6 level examined here is not an analyst price target ; it is a fallback objective tied to publicly observable technical milestones, primarily the stock's 50-day and 200-day moving averages. ADVB last traded near $2.08 , meaning a move to $6 would require roughly 190% upside — a very large move by any standard.